Leading health data platform company Datavant announced that it has signed an agreement to acquire Aetion, a leading real-world evidence (RWE) platform that powers healthcare decision-making. With this deal, Aetion will join Datavant to deliver an end-to-end RWE platform, enabling healthcare and life sciences companies to answer research questions more efficiently about the clinical impact of therapies in development and in market.
This combination combines two leaders to make RWE truly actionable, covering the full spectrum of services needed to deliver scientifically validated, transparent, and reproducible RWE accepted by global regulators, including the FDA and EMA. And Aetion brings leading technology, services and data partners to help life science and medical device customers develop decision-grade evidence plans and analyses. And stakeholders across the healthcare value chain use Datavant’s industry-standard platform for secure, compliant health data exchange to fuel connected, comprehensive insights that empower smarter decisions and advance patient outcomes.
The companies will be focusing on utilizing their complementary capabilities to create an end-to-end offering on data discovery, linkage, privacy, curation and advanced analysis to enable their ecosystem and life sciences partners to create analytics-ready insights.
This deal follows the launch of Datavant Connect powered by AWS Clean Rooms, an enhanced capability that facilitates cloud-first data discovery and evaluation to accelerate time to insight. And through Datavant Connect, ecosystem partners’ data is more easily and equitably accessible and able to be combined with complementary data sources, thus unlocking additional value to partners and customers alike.
Aetion enhances the Datavant Connect platform’s data discovery features, and will enhance privacy assessments and give end-customers clean datasets and analytics they can leverage for a range of uses. In addition, the Aetion Evidence Platform is now available in AWS Marketplace.
Aetion Activate: This announcement also coincided with the launch of Aetion Activate. And Activate expands Aetion’s software portfolio to better serve biostatisticians and data scientists, creating a collaborative, auditable, and secure platform for both code and no-code users. It also removes the burdens of manual, error-prone data preparation, freeing teams to focus on research and critical analysis. Together with Datavant’s connectivity and tokenization capabilities, Aetion now offers a more integrated ecosystem for preparing and analyzing real-world data at scale.
Upon the closing of the deal, Datavant and Aetion will have a combined ecosystem of over 300 data partners. Datavant’s RWD partners comprise datasets across electronic health records, claims, specialty pharmacy, registries, imaging, lab, social determinants of health, and more. With Aetion, RWD partners across the Datavant ecosystem will gain improved visibility of their data’s utility through sharper querying of the datasets, scaling value, demand, and additional use cases across a more expansive base of life sciences companies.
KEY QUOTES:
“As Datavant has grown and scaled, our life sciences and ecosystem partners have been asking us for a deeper capability set to bring together disparate data sources so they can tap into a more comprehensive and longitudinal view of patient health across the product lifecycle. The addition of Aetion’s team of scientists and technologists further bolsters our complementary capabilities and expertise so we can better leverage data from our ecosystem of partners to support efforts before, during, and after commercialization – generating evidence from trial to treatment and beyond to deliver life-improving therapies.”
Kyle Armbrester, Chief Executive Officer, Datavant
“Our mission at Aetion has always been to power critical decisions in healthcare with data science-driven technology. By joining forces with Datavant, we’ll unlock the full potential of real-world evidence to advance confident, data-driven decisions that improve patient care. Today, we are taking a bold step toward realizing our shared vision: a world where health data is seamlessly connected and actionable—so we can answer what treatments work, for whom, and what they should cost.”
Jeremy Rassen, ScD, CEO of Aetion
